Interviews

Brian Thornley, the Associate Vice President of Supply Excellence, Innovation and Digital Strategy at Merck, discusses what makes blockchain unique and what it could mean down the road for pharmacies.

Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discusses DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.

Data from a couple of new molecules could be encouraging for the treatment of acute myeloid leukemia and diffuse large B-cell lymphoma

In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients

Most adverse effects are very tolerable and easily managed, including headaches, diarrhea, and some neutropenias or infections

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses the results of a longer-term follow up for iFCR therapy for individuals with chronic lymphocytic leukemia .

Acalabrutinib could offer a high level of confidence for patients looking at a long course of disease.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how common chronic lymphocytic leukemia is for younger individuals

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how iFCR therapy increases the chance of functional cure for younger individuals with chronic lymphocytic leukemia.

Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the study design could affect future studies.

Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the study design and the sample demographics.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the highlights of the study and how the add-on approach affect the treatment of CLL.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses how the addition of umbralisib and ublituximab affect those being treated with ibrutinib.

Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses some of the challenges and risk of ibrutinib as treatment for CLL.

Debra Goff, PharmD, FIDSA, FCCP, infectious diseases specialist at the Ohio State University Wexner Medical Center, discusses Clostridioides difficile awareness and potential future treatments.

Minority researchers and investigators from underrepresented communities often have access to less clinical research funding than other clinical researchers.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses the challenges of treating neuroendocrine tumors in large cancer centers.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses how large cancer centers are able to manage adverse events for individuals with neuroendocrine tumors.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the cardiovascular effects of chronic kidney disease.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses how large cancer centers are able to manage care for individuals with many different physicians.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how pharmacists are limited to traditional treatment of chronic kidney disease, while waiting for new treatment options.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses promising new crystallization treatment of vascular calcification.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses the importance of pharmacists in helping treat individuals with neuroendocrine tumors.

Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses the different treatment options that could help individuals with neuroendocrine tumors, emphasizing the importance of nutrition.

Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses what the different kinds or research shows about integrative medicine and the potential risk of this treatment.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology​ at Fox Chase Cancer Center, discusses how large cancer centers provide patient-centered care.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the effects of vascular calcifications if not successfully prevented.